Tempus AI (NASDAQ:TEM) Given New $89.00 Price Target at Needham & Company LLC

Tempus AI (NASDAQ:TEM) had its target price boosted by equities research analysts at Needham & Company LLC from $75.00 to $89.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC‘s price objective would indicate a potential upside of 9.20% from the stock’s previous close.

A number of other brokerages have also recently issued reports on TEM. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Rothschild & Co Redburn began coverage on Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price for the company. Cantor Fitzgerald began coverage on Tempus AI in a research report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 price target on the stock. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Guggenheim boosted their price objective on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $73.21.

Tempus AI Price Performance

Shares of TEM stock traded up $9.28 during trading hours on Monday, hitting $81.50. 8,366,052 shares of the company’s stock were exchanged, compared to its average volume of 6,198,597. The company has a market capitalization of $14.71 billion, a PE ratio of -56.32 and a beta of 3.61. Tempus AI has a 12-month low of $40.77 and a 12-month high of $90.53. The business’s 50 day simple moving average is $70.69 and its 200-day simple moving average is $57.07. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter in the prior year, the company earned ($0.46) EPS. The firm’s revenue was up 23.1% on a year-over-year basis. On average, equities research analysts anticipate that Tempus AI will post -1.45 earnings per share for the current year.

Insider Transactions at Tempus AI

In other news, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer directly owned 106,024 shares in the company, valued at $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of Tempus AI stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the sale, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at approximately $27,903,789.43. The trade was a 6.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 1,256,777 shares of company stock worth $86,356,352. 24.26% of the stock is owned by company insiders.

Institutional Trading of Tempus AI

Large investors have recently modified their holdings of the company. Guardian Partners Inc. boosted its position in Tempus AI by 8.3% in the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after purchasing an additional 200 shares during the last quarter. Kestra Private Wealth Services LLC increased its position in Tempus AI by 1.4% in the third quarter. Kestra Private Wealth Services LLC now owns 18,685 shares of the company’s stock worth $1,530,000 after buying an additional 257 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at about $27,000. ProShare Advisors LLC lifted its position in shares of Tempus AI by 5.9% during the 3rd quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock valued at $532,000 after buying an additional 360 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC grew its stake in shares of Tempus AI by 6.7% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock valued at $525,000 after acquiring an additional 400 shares during the period. Institutional investors own 24.22% of the company’s stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus AI reported quarterly earnings of $0.07 per share, well above the consensus estimate of a $0.09 loss. Revenue increased 23.1% year over year to $411.54 million, slightly exceeding analyst expectations. The company also significantly narrowed its loss from the prior-year quarter. Tempus AI quarterly earnings report
• Positive Sentiment: The Data and Applications business grew 33% and generated gross margins above 71%. Its faster expansion is helping improve Tempus AI’s company-wide margin profile, strengthening the investment case for its higher-growth businesses. Tempus AI Revenue Up 23%; Gains Cut Net Loss
• Positive Sentiment: Management maintained its approximately $65 million adjusted EBITDA outlook. That guidance implies a substantial increase in fourth-quarter adjusted EBITDA, suggesting continued operating leverage if the company delivers. Tempus AI earnings reaction
• Positive Sentiment: Cathie Wood’s ARK Investment Management reportedly purchased approximately $11.2 million of Tempus AI stock, providing an additional signal of institutional confidence in the company’s artificial-intelligence growth prospects. Cathie Wood buys Tempus AI stock

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.